Cargando…
A missed opportunity – consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient
BACKGROUND: Levetiracetam is a frequently used drug in the therapy of partial onset, myoclonic and generalized tonic-clonic seizures. The main route of elimination is via the kidneys, which eliminate 66% of the unchanged drug as well as 24% as inactive metabolite that stems from enzymatic hydrolysis...
Autores principales: | Bahte, Svenja K, Hiss, Marcus, Lichtinghagen, Ralf, Kielstein, Jan T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006077/ https://www.ncbi.nlm.nih.gov/pubmed/24739070 http://dx.doi.org/10.1186/1471-2369-15-49 |
Ejemplares similares
-
Total collected dialysate lithium concentration after successful dialysis treatment in case of intoxication
por: Schmidt, Julius J, et al.
Publicado: (2014) -
Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023) -
Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
por: Falbo dos Reis, Pâmela, et al.
Publicado: (2021) -
Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD)
por: Claus, Robert, et al.
Publicado: (2020) -
Quantifying Missed Opportunities for Recruitment to Home Dialysis Therapies
por: Poinen, Krishna, et al.
Publicado: (2021)